Revolution Medicines, Inc. Form 4 Filings

Revolution Medicines, Inc. (RVMD) director Lorence H. Kim reported the indirect sale of a total of 56,000 shares of Common Stock on August 31, 2026 through the Lorence Kim Revocable Trust in multiple open‑market transactions at prices around $200–$206 per share. The filing also shows 1,191 restricted stock units held directly and states that these sales were made under a Rule 10b5-1 trading plan adopted by the trust on June 1, 2026.

Revolution Medicines, Inc. (RVMD) reported that its General Counsel, Jeff Cislini, exercised stock options and sold common shares on August 21, 2026 under a Rule 10b5-1 trading plan adopted on May 22, 2026. He exercised options for 56,280 shares of common stock at exercise prices of $18.56 and $21.61 per share and sold an aggregate of 56,894 shares of common stock in multiple trades at weighted average prices ranging from about $206.76 to $212.74 per share. Cislini’s holdings include 43,514 restricted stock units that remain outstanding.

Revolution Medicines, Inc. (RVMD) reported that President and Chief Executive Officer Mark A. Goldsmith exercised options for 80,000 shares of common stock at an exercise price of $4.73 per share and, on the same date, sold an aggregate of 86,000 shares of common stock in multiple transactions at weighted average prices between $206.78 and $212.74, including sales through revocable trusts. The filing notes that these transactions were made pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026, and that his reported holdings include 182,938 restricted stock units.

Revolution Medicines director Sushil Patel reported option exercises and share sales in RVMD stock. On June 29, 2026, he exercised stock options to acquire 2,955 shares of common stock at an exercise price of $37.54 per share and sold 5,580 shares in a series of open-market transactions.

The sales were executed at weighted-average prices within ranges from $182.93 to $192.64 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. After these transactions, Patel directly held 21,656 common shares, including 1,191 restricted stock units.

Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported a combination of stock sales and an option exercise in company shares. On June 24, 2026, he sold 20,000 shares of common stock in multiple open-market transactions at prices generally around $167–$170 per share, executed under a Rule 10b5-1 trading plan adopted on March 24, 2026. On the same date, he exercised stock options to acquire 20,000 shares of common stock at an exercise price of $18.56 per share. After these transactions, he directly owns 123,269 shares of Revolution Medicines common stock, which includes 51,388 restricted stock units.

Revolution Medicines, Inc. reported that director Kim Lorence H. received new equity compensation awards. The director was granted 1,191 shares of Common Stock in the form of restricted stock units at no cash cost, increasing direct holdings to 74,281 shares. In addition, the director received a stock option for 3,127 shares of Common Stock with an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as the director continues as a service provider under the company’s 2020 Plan.

Revolution Medicines director Alexis Borisy reported equity awards from the company. He received 1,191 shares of Common Stock as a grant, bringing his direct holdings to 2,340,075 shares after the transaction. He was also granted options to purchase 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036.

The 1,191 granted shares are structured as restricted stock units. The option will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as Borisy continues as a Service Provider under the company’s 2020 Plan.

Revolution Medicines director Elizabeth M. Anderson reported compensation-related equity grants and updated holdings. She received 1,191 shares of common stock as a grant of restricted stock units and a stock option for 3,127 shares at an exercise price of $162.99 per share.

The option covers 3,127 shares of common stock and expires on June 18, 2036. These option shares vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, assuming she continues as a service provider.

After these awards, Anderson directly holds 9,406 shares of common stock, which include the 1,191 restricted stock units. Separately, 26,990 shares of common stock are held indirectly through the David W. Anderson 1996 Irrevocable Trust.

Revolution Medicines director Sandra Horning reported equity compensation awards. She received 1,191 shares of common stock at no cost, bringing her direct holdings to 97,765 shares, which include 6,083 restricted stock units. She was also granted a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036.

The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting, as long as she continues to serve as a service provider under the company’s 2020 plan.

Revolution Medicines director Frank Clyburn reported receiving equity awards in the form of common stock and stock options. He was granted 1,191 shares of Common Stock, increasing his direct holdings to 10,929 shares, and a separate grant of 3,127 Stock Options (Right to Buy) with a $162.99 exercise price, each option for one share of common stock.

The option grant will vest in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next annual meeting following the grant date, as long as he remains a Service Provider under the company’s 2020 Plan through that vesting date. The filing also notes that his holdings include 4,080 restricted stock units, which typically convert into shares over time.

Revolution Medicines, Inc. director Sushil Patel reported equity awards consisting of common stock and stock options. He received 1,191 shares of Common Stock, which include 1,191 restricted stock units. Following this award, he directly holds 24,281 common shares.

He also received a stock option covering 3,127 shares of Common Stock at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the annual meeting following the grant date, subject to his continued service.

Revolution Medicines director Flavia Borellini received new equity awards. She was granted 1,191 shares of common stock in the form of Restricted Stock Units, increasing her direct holdings to 26,215 common shares. She also received a stock option for 3,127 shares at an exercise price of $162.99 per share, expiring on June 18, 2036. The option vests in full on the earlier of the first anniversary of June 18, 2026 or immediately before the next Annual Meeting after the grant date, as long as she remains a service provider under the company’s 2020 Plan.

Revolution Medicines executive Anthony Mancini reported an automatic sale of shares to cover taxes on vested stock units. On the transaction date, 4,615 shares of common stock were sold in open-market trades at a weighted average price of $156.1192 per share.

The filing explains that this was an automatic sell-to-cover solely for applicable withholding taxes following restricted stock unit vesting, rather than a discretionary sale. After the transaction, Mancini held 49,975 shares directly, including 43,700 restricted stock units and 190 shares acquired under the company’s Employee Stock Purchase Plan.

Revolution Medicines director and officer Mark A. Goldsmith reported an open-market sale of 10,020 shares of common stock on June 16, 2026 at a weighted average price of $156.1188 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations from restricted stock unit vesting.

Following this sale, Goldsmith directly holds 267,330 shares of Revolution Medicines common stock, which includes 182,938 restricted stock units and 652 shares acquired under the company’s Employee Stock Purchase Plan. He also has additional indirect holdings through family revocable trusts.

Revolution Medicines, Inc. General Counsel Jeff Cislini reported an open-market sale of 2,157 shares of common stock at a weighted average price of $156.1191 per share. The trade was executed under a Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. After this transaction, he holds 56,521 shares, including 43,514 restricted stock units and 160 shares acquired through the company’s Employee Stock Purchase Plan.

Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,722 shares of common stock at an average price of $156.1192 per share. The sale was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs, and Jack now holds 123,269 shares, including 51,388 RSUs and 479 shares acquired through the employee stock purchase plan.

Revolution Medicines, Inc. executive Stephen Michael Kelsey reported an open-market sale of 4,175 shares of common stock on June 16, 2026 at a weighted average price of $156.1192 per share. The footnotes state this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter intended to satisfy tax withholding obligations related to vested restricted stock units. After the sale, Kelsey directly owned 291,876 shares, which the disclosure notes includes 76,251 RSUs and 653 shares acquired through the company’s Employee Stock Purchase Plan.

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a mix of option exercises and stock sales. On June 15 and June 17, 2026, she exercised stock options covering a total of 90,000 shares of common stock at exercise prices of $26.50, $29.80, and $40.74 per share.

Across June 15 and June 17, 2026 and June 16, 2025, she sold 93,575 shares of common stock in open-market transactions at weighted average prices around $156–$160 per share. Footnotes state that the 2026 transactions were effected under a Rule 10b5-1 trading plan and that an earlier Rule 10b5-1 instruction letter addressed tax withholding obligations on RSU vesting.

After these transactions, Horn continues to hold a significant direct equity position, including restricted stock units noted in the footnotes.

Revolution Medicines, Inc. reported insider activity by Chief Operating Officer Margaret A. Horn. On June 11, 2026, she exercised stock options to acquire a total of 10,000 shares of common stock at exercise prices of $40.74 and $42.45 per share. The same day, she sold 10,000 shares of common stock in open-market transactions at prices ranging from $143.78 to $150.15 per share. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 12, 2026, indicating a planned exercise-and-sell pattern rather than ad hoc trading.

Revolution Medicines, Inc. officer Anthony Mancini reported mixed equity transactions in company common stock. He sold a total of 3,121 shares in open-market transactions at weighted average prices in the low $150s per share and exercised stock options for 3,121 shares at an exercise price of $33.62 per share.

The filing shows this activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 24, 2025. Following the transactions, Mancini directly holds 54,400 shares of common stock, which a footnote states includes 54,400 Restricted Stock Units, indicating these trades represent a small portion of his overall reported equity position.

Revolution Medicines, Inc. (RVMD) insider Anthony Mancini reported a pre-planned exercise-and-sell transaction in company stock. On April 27, 2026, he exercised stock options for 3,120 shares of common stock at an exercise price of $33.62 per share.

The same day, he executed three open-market sales totaling 3,120 shares of common stock at weighted average prices around $131–$134 per share, under a Rule 10b5-1 trading plan adopted on December 24, 2025. Following these transactions, he held 54,400 shares or restricted stock units directly, according to the filing.

Revolution Medicines, Inc. director and officer Mark A. Goldsmith exercised stock options and sold shares of common stock. He exercised options for 23,244 shares at an exercise price of $4.09 and 96,756 shares at $4.73, receiving an equal number of common shares. He then sold 120,000 common shares at a weighted average price of $150.0874 in open-market transactions made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. After these transactions, he held 276,698 common shares directly, including 201,150 restricted stock units, and additional indirect holdings through family trusts.

Revolution Medicines, Inc. officer Anthony Mancini exercised options and sold shares of common stock. He exercised options for 37,450 shares of common stock at an exercise price of $33.6200 per share and received 37,450 shares.

On the same date, he sold a total of 37,450 shares in multiple open-market transactions at prices ranging from $93.2230 to $97.2071, pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. After these transactions, he directly holds 54,800 shares of common stock, which the footnotes state includes 54,400 restricted stock units.

Revolution Medicines, Inc. Chief Medical Officer Wei Lin reported an open-market sale of 2,073 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on December 23, 2024 to satisfy tax withholding obligations upon the vesting of restricted stock units after March 15, 2025. Following this sale, Lin holds 101,366 shares directly, which the disclosure states includes 62,050 restricted stock units.

Revolution Medicines, Inc. officer Stephen Michael Kelsey reported an open-market sale of 4,302 shares of Common Stock at 99.4804 per share. The transaction was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon vesting of restricted stock units. After this sale, he directly owns 295,398 shares, which includes 84,250 restricted stock units.

Revolution Medicines director Mark A. Goldsmith sold 12,871 shares of common stock in an open-market transaction at an average price of $99.4804 per share on March 17, 2026. The sale was made under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations from vesting restricted stock units.

After the sale, he holds 276,698 shares directly, including 201,150 RSUs. He also has indirect holdings through trusts, with reported positions of 594,060, 64,424, and 64,424 shares of common stock held in separate revocable trusts.

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported an open-market sale of 4,583 shares of common stock at an average price of $99.4804 per share. After this transaction, she directly holds 157,570 shares. A footnote states the sale was executed under a Rule 10b5-1 instruction letter to satisfy tax withholding obligations related to vesting restricted stock units.

Revolution Medicines, Inc. Chief Financial Officer Anders Jack reported an open-market sale of 2,753 shares of common stock at an average price of $99.4804 per share. The transaction was made pursuant to a pre-established Rule 10b5-1 instruction letter to satisfy tax withholding obligations on vested RSUs. Following the sale, he directly holds 125,512 shares, which include 56,600 restricted stock units.

Revolution Medicines General Counsel Jeff Cislini reported selling 2,958 shares of common stock in two open-market transactions. On March 17, he sold 1,795 shares at $99.4804 per share, and on March 19 he sold 1,163 shares at $97.44 per share. One sale was made under a Rule 10b5-1 instruction letter related to tax withholding on vested RSUs, and the other under a 10b5-1 trading plan. After these sales, he directly holds 58,518 shares, including 48,125 RSUs.

Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. Following the sale, Wang holds 116,063 shares directly, including 48,700 restricted stock units.

Revolution Medicines, Inc. director Elizabeth M. Anderson reported two bona fide gifts of common stock totaling 30,000 shares. The gifts, coded as "G" transactions, occurred on March 4, 2026 at a reported price of $0.00 per share, indicating non-cash charitable or personal transfers.

After these transactions, Anderson holds 8,215 shares directly and 26,990 shares indirectly. The indirect holdings include 3,142 restricted stock units and shares held by trusts, including the Irrevocable Deed of Trust of David W. Anderson and Elizabeth M. Anderson and the David W. Anderson 1996 Irrevocable Trust.

Revolution Medicines, Inc. reported that officer Xiaolin Wang received equity awards on March 1, 2026. Wang was granted stock options for 34,000 shares at an exercise price of $0.00 and 15,100 shares of common stock, both as awards rather than open-market purchases.

Following the common stock grant, Wang directly owned 118,073 common shares, which includes 54,464 restricted stock units and 652 shares acquired under the employee stock purchase plan. The option award vests in equal monthly installments over four years starting March 1, 2026, contingent on continued service.

Revolution Medicines Chief Medical Officer Wei Lin reported equity awards that increase his stake in the company. He received a stock option for 34,000 shares at an exercise price of $0.00 per share and a direct grant of 15,100 shares of common stock.

After these awards, Lin directly holds 103,439 shares of common stock, which includes 68,000 restricted stock units. The option vests in equal monthly installments over four years starting on March 1, 2026, contingent on his continued service with the company.

Revolution Medicines, Inc. officer Stephen Michael Kelsey reported equity awards that increased his direct holdings. He received a stock option covering 47,600 shares of common stock at an exercise price of $0.00 per share, characterized as a grant or award acquisition. He also acquired 21,100 shares of common stock as a separate grant, bringing his directly held common shares to 299,700, which includes 94,676 restricted stock units. The option vests in equal monthly installments over four years starting March 1, 2026, with one forty-eighth of the shares vesting each month so that all option shares are fully vested on the fourth anniversary, contingent on his continued service.

Revolution Medicines director and officer Mark A. Goldsmith reported option grants, share awards, option exercises and planned sales in RVMD stock. On March 1, 2026, he received stock options for 128,600 shares and 57,100 shares of common stock as grants, with the options vesting monthly over four years starting March 1, 2026.

On March 2, 2026, he exercised 30,000 stock options and acquired 30,000 common shares, then related accounts sold a total of 36,000 common shares in multiple open‑market trades around $98–$102 per share, including sales by family trusts under a Rule 10b5‑1 trading plan. After these transactions, he held 318,869 common shares directly plus additional shares indirectly through trusts, including 225,863 restricted stock units.

Horn Margaret A reported acquisition or exercise transactions in this Form 4 filing.

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported equity awards consisting of a stock option for 47,600 shares and a grant of 21,100 shares of common stock. The option vests in equal monthly installments over four years starting March 1, 2026, contingent on her continued service.

Revolution Medicines, Inc. reported that General Counsel Jeff Cislini received equity awards. He was granted a stock option for 32,500 shares at an exercise price of $0.00 and an award of 14,500 shares of common stock. The option vests in equal monthly installments over four years starting on March 1, 2026, becoming fully vested on the fourth anniversary, subject to his continued service.

Revolution Medicines, Inc. reported that Chief Financial Officer Anders Jack acquired new equity awards. On March 1, 2026, he received a stock option covering 45,400 shares at an exercise price of $0.00 per share and a grant of 20,200 shares of common stock, both recorded as direct ownership.

The filing states that shares held include 62,538 restricted stock units. The option vests in equal monthly installments over 48 months starting March 1, 2026, so that all 45,400 option shares are fully vested and exercisable by the fourth anniversary, contingent on his continued service.

Revolution Medicines President and CEO Mark A. Goldsmith, who also serves as a director, reported an option exercise and updated share holdings. On February 6, 2026, a stock option for 24,010 shares with a $0.54 exercise price was converted into the same number of common shares.

Following the transaction, Goldsmith directly held 256,479 shares of common stock, which the filing notes includes 168,763 restricted stock units570,050 shares in the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and 67,424 shares in each of two additional revocable trusts.

Revolution Medicines’ general counsel, Jeff Cislini, reported a small, pre-planned stock sale. On January 21, 2026, he sold 908 shares of Revolution Medicines common stock at $115.60 per share under a Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, he beneficially owned 46,976 shares, which include 38,769 restricted stock units that typically vest over time.

Revolution Medicines, Inc. Chief Operating Officer Margaret A. Horn reported a series of option exercises and share sales on January 7, 2026. She exercised stock options for 51,406 shares of common stock at $42.45 per share and 23,594 shares at $29.80 per share, then sold 53,096, 20,204 and 1,700 shares of common stock at weighted average prices of $100.0164, $101.7928 and $102.90, respectively. The transactions were made under a Rule 10b5-1 trading plan adopted on March 7, 2025. After these trades, she directly beneficially owned 141,053 shares of common stock, which include 61,226 restricted stock units, and held remaining stock options covering 1,094 and 119,906 shares with vesting described in the filing.

Revolution Medicines Chief Financial Officer Jack Anders reported an exercise and sale of company stock. On January 7, 2026, he exercised a stock option for 10,000 shares of common stock at an exercise price of $42.45 per share, then sold 10,000 shares of common stock at a price of $98 per share. The filing states this activity was carried out under a Rule 10b5-1 trading plan adopted on December 16, 2024, indicating it was pre‑scheduled. Following these transactions, Anders beneficially owned 108,065 shares of common stock, which includes 42,338 restricted stock units, and held 15,900 stock options directly.

Revolution Medicines, Inc. reported an insider transaction by its General Counsel, who filed a Form 4 as a single reporting person. On 12/16/2025, the officer sold 2,688 shares of common stock at a price of $76.8169 per share. After this sale, the reporting person beneficially owned 47,884 shares.

The transaction was made pursuant to a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to satisfy tax withholding obligations upon vesting of restricted stock units (RSUs) after July 15, 2023. The reported holdings include 147 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025, and 38,769 RSUs, which represent additional equity that may be delivered over time as they vest.

Revolution Medicines, Inc. insider transaction: President and Chief Executive Officer Mark A. Goldsmith, who is also a director, reported selling 15,394 shares of Revolution Medicines common stock on 12/16/2025 at a price of $76.8173 per share. The sale was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to cover tax withholding obligations arising from the vesting of restricted stock units.

After this transaction, Goldsmith beneficially owns 232,469 shares directly, which includes 168,763 restricted stock units. He also holds additional indirect interests through trusts, including 67,424 shares held by the Jonathan Goldsmith Revocable Trust, 67,424 shares held by the Rebecca Goldsmith Revocable Trust, and 570,050 shares held by the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Revolution Medicines, Inc. reported that officer Stephen Michael Kelsey, President of Research and Development, disposed of 5,447 shares of common stock on 12/16/2025 at a price of $76.8172 per share. This sale was coded as an "S" transaction and was made under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to cover tax withholding obligations related to restricted stock unit (RSU) vesting after July 15, 2023. Following this transaction, Kelsey beneficially owned 278,600 shares of common stock, including 73,576 RSUs.

Revolution Medicines, Inc. Chief Operating Officer Margaret Horn reported a sale of company stock in an insider filing. On 12/16/2025, she disposed of 4,847 shares of common stock at a price of $76.8173 per share. The filing states this transaction was executed under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023, to cover tax withholding obligations triggered by the vesting of restricted stock units.

After this transaction, Horn beneficially owned 141,053 shares of Revolution Medicines common stock, which includes 61,226 restricted stock units. The form indicates the holdings are directly owned.

Revolution Medicines, Inc. Chief Financial Officer reports a planned share sale. CFO Jack Anders disclosed the sale of 3,104 shares of common stock on 12/16/2025 at a price of $77.0904 per share. The transaction was made under a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy his tax withholding obligations upon the vesting of restricted stock units after July 15, 2023.

Following this transaction, Anders beneficially owns 108,065 shares of Revolution Medicines common stock. This figure includes 175 shares acquired under the company’s Employee Stock Purchase Plan on November 30, 2025 and 42,338 restricted stock units, which represent a right to receive shares in the future subject to vesting conditions.

Revolution Medicines, Inc. (RVMD) reported an insider stock transaction by its Chief Financial Officer, Jack Anders. On 11/25/2025, Anders exercised a stock option for 5,418 shares of common stock at an exercise price of $17 per share, then sold 5,418 shares of common stock at a price of $74 per share. The filing notes that the transaction was made under a Rule 10b5-1 trading plan adopted on December 16, 2024, which is designed to pre-arrange trades. After these transactions, Anders directly holds 110,994 shares of common stock, which includes 48,275 restricted stock units.

Revolution Medicines, Inc. (RVMD) reported insider activity by President, Chief Executive Officer and Director Mark A. Goldsmith. On 11/25/2025, he exercised a stock option to buy 60,000 shares of common stock at an exercise price of $4.09 per share, then sold 60,000 shares of common stock in a transaction under code M/S.

He also reported open market sales of 3,000 shares of common stock at $75 per share from each of two trusts. A weighted average sale price of $75.0827 was reported for one of the sales executed in multiple trades. After these transactions, he directly beneficially owned 247,863 shares of common stock (including 193,475 restricted stock units), and held additional indirect positions of 67,424 shares in each of two revocable trusts and 570,050 shares in a separate revocable living trust. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.